One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2019-129962
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 3 |
Affiliation: Vanderbilt University, The University of Texas MD Anderson Cancer Center, Cornell University, Presbyterian Hospital, University of Southern California, The Ohio State University, Mayo Clinic, Princess Margaret Cancer Centre, University of Chicago Medical Center, Roswell Park Cancer Institute, Sarah Cannon, Columbia University Irving Medical Center, Yale University, Temple University
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
